.: ORİJİNAL ARAŞTIRMA
Restenoz Hastalarında Serum ApoM ve Serum Lipid Seviyeleri Arasındaki İlişkinin Araştırılması
The Relationship Between Serum ApoM and Lipid Levels in Restenosis Patients
Turkiye Klinikleri J Cardiovasc Sci. 2020;32(2):75-83
doi: 10.5336/cardiosci.2020-75998
Makale Dili: TR
Tam Metin
ÖZET
Amaç: Apolipoprotein M (ApoM) çoğunlukla (~%5) yüksek yoğunluklu lipoprotein (HDL) ve az miktarda (<%2) düşük yoğunluklu lipoprotein (LDL) içeriğinde bulunan yeni bir antiaterosklerotik proteindir. Ters kolesterol transportu aracılığıyla HDL metabolizmasında önemli rol oynadığı bilinen ApoM'nin, son çalışmalarda LDL oksidasyonu ve ateroskleroza karşı koruyucu etkileri olduğu belirtilmiştir. Buna karşın ApoM ve hastalıkların ilişkisini araştıran klinik çalışmalar sınırlı sayıdadır. Bu sebeple ApoM'nin kolesterol metabolizmasındaki etkilerine dayanarak çalışmamızda, restenoz hastalarında ve sağlıklı kontrollerde serum ApoM ve lipid seviyeleri arasındaki ilişkiyi araştırmayı amaçladık. Bu çalışma, restenoz hastalarında serum ApoM ve lipid seviyeleri arasındaki ilişkiyi gösteren literatürdeki ilk çalışmadır. Gereç ve Yöntemler: Çalışmamıza, 36 restenoz hastası ve 42 sağlıklı kontrol dâhil edilmiştir. Serum ApoM seviyeleri, ELISA yöntemiyle ölçülmüştür. Bulgular: Hasta grubunda serum ApoM (p=0,022), totalkolesterol (Total-K) (p=0,008) ve HDL-kolesterol (HDL-K) (p<0,001) seviyeleri sağlıklı kontrollerden daha düşük bulunurken, açlık kan glukozu ve HbA1c (p<0,001) ve trigliserid (TG) seviyeleri (p=0,002) yüksek bulunmuştur. Ayrıca restenoz hastalarında yüksek TG (≥150 mg/dL) ve LDL-kolesterol (LDL-K) (≥130 mg/dL) risk eşik değerlerinin, yüksek ApoM seviyeleri ile ilişkili olduğu tespit edilmiştir (sırasıyla, p=0,038; p=0,041). Bu ilişki kontrol grubunda gözlenmemiştir (p>0,05). Sonuç: Restenoz hastalarında, serum ApoM seviyeleri yalnızca HDL-K ile değil aynı zamanda Total-K, TG ve LDL-K seviyeleri ile de anlamlı pozitif korelasyon göstermiştir. Bu sonuçlar ApoM seviyelerinin, TG ve kolesterol seviyelerine etki ederek restenoz gelişimine katkı sağlayabileceğini göstermektedir.
Anahtar Kelimeler: Apolipoprotein M; HDL; LDL; kolesterol; trigliserid; restenoz
Amaç: Apolipoprotein M (ApoM) çoğunlukla (~%5) yüksek yoğunluklu lipoprotein (HDL) ve az miktarda (<%2) düşük yoğunluklu lipoprotein (LDL) içeriğinde bulunan yeni bir antiaterosklerotik proteindir. Ters kolesterol transportu aracılığıyla HDL metabolizmasında önemli rol oynadığı bilinen ApoM'nin, son çalışmalarda LDL oksidasyonu ve ateroskleroza karşı koruyucu etkileri olduğu belirtilmiştir. Buna karşın ApoM ve hastalıkların ilişkisini araştıran klinik çalışmalar sınırlı sayıdadır. Bu sebeple ApoM'nin kolesterol metabolizmasındaki etkilerine dayanarak çalışmamızda, restenoz hastalarında ve sağlıklı kontrollerde serum ApoM ve lipid seviyeleri arasındaki ilişkiyi araştırmayı amaçladık. Bu çalışma, restenoz hastalarında serum ApoM ve lipid seviyeleri arasındaki ilişkiyi gösteren literatürdeki ilk çalışmadır. Gereç ve Yöntemler: Çalışmamıza, 36 restenoz hastası ve 42 sağlıklı kontrol dâhil edilmiştir. Serum ApoM seviyeleri, ELISA yöntemiyle ölçülmüştür. Bulgular: Hasta grubunda serum ApoM (p=0,022), totalkolesterol (Total-K) (p=0,008) ve HDL-kolesterol (HDL-K) (p<0,001) seviyeleri sağlıklı kontrollerden daha düşük bulunurken, açlık kan glukozu ve HbA1c (p<0,001) ve trigliserid (TG) seviyeleri (p=0,002) yüksek bulunmuştur. Ayrıca restenoz hastalarında yüksek TG (≥150 mg/dL) ve LDL-kolesterol (LDL-K) (≥130 mg/dL) risk eşik değerlerinin, yüksek ApoM seviyeleri ile ilişkili olduğu tespit edilmiştir (sırasıyla, p=0,038; p=0,041). Bu ilişki kontrol grubunda gözlenmemiştir (p>0,05). Sonuç: Restenoz hastalarında, serum ApoM seviyeleri yalnızca HDL-K ile değil aynı zamanda Total-K, TG ve LDL-K seviyeleri ile de anlamlı pozitif korelasyon göstermiştir. Bu sonuçlar ApoM seviyelerinin, TG ve kolesterol seviyelerine etki ederek restenoz gelişimine katkı sağlayabileceğini göstermektedir.
Anahtar Kelimeler: Apolipoprotein M; HDL; LDL; kolesterol; trigliserid; restenoz
ABSTRACT
Objective: Apolipoprotein M (ApoM) is a novel antiatherosclerotic protein which is present predominantly (~5%) in high density lipoprotein (HDL) and in trace amounts (<2%) in low density lipoprotein (LDL). In recent studies, it is reported that ApoM which is known to play important role in HDL metabolism via revers cholesterol transport, has protective effects against LDL oxidation and atherosclerosis. However, clinical studies revealing the association between ApoM and diseases are very limited. Therefore, we aimed to investigate the relationship between serum ApoM and lipid levels in restenosis patients and healthy controls on the basis of its effects on cholesterol metabolism. This is the first study revealing the association between serum ApoM and lipid levels in restenosis patients. Material and Methods: Thirty-six restenosis patients and 42 healthy controls were included in our study. Serum ApoM levels were measured by ELISA method. Results: The serum ApoM (p=0.022), total-cholesterol (Total-C) (p=0.008) and HDLcholesterol (HDL-C) (p<0.001) levels of patients were lower than the control group, while fasting blood glucose, HbA1c (p<0.001) and triglyceride (TG) (p=0.002) levels were higher. In addition, higher risk threshold values for serum TG (≥150 mg/dL) and LDL-cholesterol (LDL-C) (≥130 mg/dL) in the restenosis group were detected to be associated with higher ApoM levels in the restenosis patient group (p=0.038 and p=0.041, respectively). However, this relationship was not observed in control group (p>0.05). Conclusion: Serum ApoM level exhibited a significant, positive correlation not only with the HDL-C level, but also with the Total-C, TG and LDL-C levels in patients with restenosis. These results indicated that the serum ApoM levels may affects the serum TG and cholesterol levels so that contributes to the development of restenosis.
Keywords: Apolipoprotein M; HDL; LDL; cholesterol; triglyceride; restenosis
Objective: Apolipoprotein M (ApoM) is a novel antiatherosclerotic protein which is present predominantly (~5%) in high density lipoprotein (HDL) and in trace amounts (<2%) in low density lipoprotein (LDL). In recent studies, it is reported that ApoM which is known to play important role in HDL metabolism via revers cholesterol transport, has protective effects against LDL oxidation and atherosclerosis. However, clinical studies revealing the association between ApoM and diseases are very limited. Therefore, we aimed to investigate the relationship between serum ApoM and lipid levels in restenosis patients and healthy controls on the basis of its effects on cholesterol metabolism. This is the first study revealing the association between serum ApoM and lipid levels in restenosis patients. Material and Methods: Thirty-six restenosis patients and 42 healthy controls were included in our study. Serum ApoM levels were measured by ELISA method. Results: The serum ApoM (p=0.022), total-cholesterol (Total-C) (p=0.008) and HDLcholesterol (HDL-C) (p<0.001) levels of patients were lower than the control group, while fasting blood glucose, HbA1c (p<0.001) and triglyceride (TG) (p=0.002) levels were higher. In addition, higher risk threshold values for serum TG (≥150 mg/dL) and LDL-cholesterol (LDL-C) (≥130 mg/dL) in the restenosis group were detected to be associated with higher ApoM levels in the restenosis patient group (p=0.038 and p=0.041, respectively). However, this relationship was not observed in control group (p>0.05). Conclusion: Serum ApoM level exhibited a significant, positive correlation not only with the HDL-C level, but also with the Total-C, TG and LDL-C levels in patients with restenosis. These results indicated that the serum ApoM levels may affects the serum TG and cholesterol levels so that contributes to the development of restenosis.
Keywords: Apolipoprotein M; HDL; LDL; cholesterol; triglyceride; restenosis
REFERANSLAR:
- Mendis S, Puska P, Norrving B; World Health Organization. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011. p.166.
- Onat A, Aydin M, Köroğlu B, Ornek E, Altay S, Celik E, et al. [TARF Survey 2011: mortality and performance in the long-term follow-up]. Turk Kardiyol Dern Ars. 2012;40(2):117-21. [Crossref] [PubMed]
- Thanassoulis G, Vasan RS. Genetic cardiovascular risk prediction: will we get there? Circulation. 2010;122(22):2323-34. [Crossref] [PubMed] [PMC]
- Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551-62. [Crossref] [PubMed]
- Mendis S, Nordet P, Fernandez-Britto JE, Sternby N; For the Pathobiological Determinants of Atherosclerosis in Youth (PBDAY) Research Group. Atherosclerosis in children and young adults: An overview of the World Health Organization and International Society and Federation of Cardiology Study on Pathobiological Determinants of Atherosclerosis in Youth Study (1985-1995). Prevention and Control. 2005;1(1):3-15. [Crossref]
- Davis NE. Atherosclerosis--an inflammatory process. J Insur Med. 2005;37(1):72-5.
- Borissoff JI, Heeneman S, Kilinç E, Kassák P, Van Oerle R, Winckers K, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010;122(8):821-30. [Crossref] [PubMed]
- Nordmann AJ, Hengstler P, Leimenstoll BM, Harr T, Young J, Bucher HC. Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2004;25(1):69-80. [Crossref] [PubMed]
- Indolfi C, Pavia M, Angelillo IF. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol. 2005;95(10):1146-52. [Crossref] [PubMed]
- Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J. 2009;73(4):615-21. [Crossref] [PubMed]
- Xu N, Dahlbäck B. A novel human apolipoprotein (apoM). J Biol Chem. 1999;274(44):31286-90. [Crossref] [PubMed]
- Huang LZ, Gao JL, Pu C, Zhang PH, Wang LZ, Feng G, et al. Apolipoprotein M: research progress, regulation and metabolic functions (Review). Mol Med Rep. 2015;12(2):1617-24. [Crossref] [PubMed]
- Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlbäck B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res. 2006;47(8):1833-43. [Crossref] [PubMed]
- Sramkova V, Berend S, Siklova M, Caspar-Bauguil S, Carayol J, Bonnel S, et al. Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction. Am J Clin Nutr. 2019;109(6):1499-510. [Crossref] [PubMed]
- Tavernier G, Caspar-Bauguil S, Viguerie N. Apolipoprotein M: new connections with diet, adipose tissue and metabolic syndrome. Curr Opin Lipidol. 2020;31(1):8-14. [Crossref] [PubMed]
- Wang X, Wang F. Vascular protection by high-density lipoprotein-associated sphingosine-1- phosphate. J Geriatr Cardiol. 2017;14(11):696-702.
- Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock out mice. J Biol Chem. 2008;283(4):1839 47. [Crossref] [PubMed]
- Santamarina Fojo S, Lambert G, Hoeg JM, Brewer Jr HB. Lecithin cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol. 2000;11(3):267 75. [Crossref] [PubMed]
- Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 2005;11(4):418 22. [Crossref] [PubMed]
- Xu WW, Zhang Y, Tang YB, Xu YL, Zhu HZ, Ferro A, et al . A genetic variant of apolipo-protein M increases susceptibility to coronary artery disease in a Chinese population. Clin Exp Pharmacol Physiol. 2008;35(5-6):546 51. [Crossref] [PubMed]
- Jiao GQ, Yuan ZX, Xue YS, Yang CJ, Lu CB, Lu ZQ, et al. A prospective evaluation of apolipoprotein M gene T 778C polymorphism in relation to coronary artery disease in Han Chinese. Clin Biochem. 2007;40(15):1108 12. [Crossref] [PubMed]
- Zhang Z, Chu G, Yin RX. Apolipoprotein M T 778C polymorphism is associated with serum lipid levels and the risk of coronary artery disease in the Chinese population: a meta analysis. Lipids Health Dis. 2013;12:135. [Crossref] [PubMed] [PMC]
- Zhou JW, Tsui SKW, Ng MCY, Geng H, Li SK, So WY, et al. Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes. PLoS One. 2011;6(2):e17324. [Crossref] [PubMed] [PMC]
- Huang Y, Liu Y, Jiang L, Sun R, Zhang H, Liu R, Xu N. Apolipoprotein m (APOM) levels and APOM rs805297 G/T polymorphism are associated with increased risk for rheumatoid arthritis. Joint Bone Spine. 2014;81(1):32-6. [Crossref] [PubMed]
- Burkart KM, Manichaikul A, Wilk JB, Ahmed FS, Burke GL, Enright P, et al. APOM and high density lipoprotein cholesterol are associated with lung function and per cent emphysema. Eur Respir J. 2014;43(4):1003 17. [Crossref] [PubMed] [PMC]
- Christoffersen C, Nielsen LB. Apolipoprotein M: bridging HDL and endothelial function. Curr Opin Lipidol. 2013;24(4):295-300. [Crossref] [PubMed]
- Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev. 2011;111(10):6299-320. [Crossref] [PubMed] [PMC]
- Frej C, Linder A, Happonen KE, Taylor FB, Lupu F, Dahlbäck B. Sphingosine 1-phosphate and its carrier apolipoprotein M in human sepsis and in Escherichia coli sepsis in baboons. J Cell Mol Med. 2016;20(6):1170-81. [Crossref] [PubMed] [PMC]
- Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS, et al. High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol. 2010;298(3):H1022-8. [Crossref] [PubMed] [PMC]
- Sattler K, Gräler M, Keul P, Weske S, Reimann CM, Jindrová H, et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol. 2015;66(13):1470-85. [Crossref] [PubMed]
- Kurano M, Tsuneyama K, Morimoto Y, Shimizu T, Jona M, Kassai H, et al. Apolipoprotein M protects lipopolysaccharide-treated mice from death and organ injury. Thromb Haemost. 2018;118(6):1021-35. [Crossref] [PubMed]
- Kappelle PJWH, Ahnström J, Dikkeschei BD, de Vries R, Sluiter WJ, Wolffenbuttel BHR, et al. Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. Atherosclerosis. 2010;213(1):247-50. [Crossref] [PubMed]
- Thongtang N, Diffenderfer MR, Ooi EMM, Barrett PHR, Turner SM, Le NA, et al. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin. J Lipid Res. 2017;58(7):1315-24. [Crossref] [PubMed] [PMC]
- Ahnström J, Axler O, Jauhiainen M, Salomaa V, Havulinna AS, Ehnholm C, et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res. 2008;49(9):1912-7. [Crossref] [PubMed]
- Chirinos JA, Zhao L, Jia Y, Frej C, Adamo L, Mann D, et al. Reduced apolipoprotein M and adverse outcomes across the spectrum of human heart failure. Circulation. 2020;141(18):1463-76. [Crossref] [PubMed]
- Memon AA, Bennet L, Zöller B, Wang X, Palmér K, Dahlbäck B, et al. The association between apolipoprotein M and insulin resistance varies with country of birth. Nutr Metab Cardiovasc Dis. 2014;24(11):1174-80. [Crossref] [PubMed]
- Kurano M, Tsukamoto K, Shimizu T, Kassai H, Nakao K, Aiba A, et al. Protection against insulin resistance by apolipoprotein M/sphingosine-1-phosphate. Diabetes. 2020;69(5):867-81. [Crossref] [PubMed]
- Frej C, Mendez AJ, Ruiz M, Castillo M, Hughes TA, Dahlbäck B, et al. A shift in ApoM/S1P between HDL-particles in women with type 1 diabetes mellitus is associated with impaired anti-inflammatory effects of the ApoM/S1P complex. Arterioscler Thromb Vasc Biol. 2017;37(6):1194-205. [Crossref] [PubMed]
- He L, Wu P, Tan L, Le B, Du W, Shen T, et al. Characteristics of lipid metabolism including serum apolipoprotein M levels in patients with primary nephrotic syndrome. Lipids Health Dis. 2017;16(1):167. [Crossref] [PubMed] [PMC]
- Sørensen IM, Bertelsen M, Freese E, Lindhard K, Ullum H, Feldt-Rasmussen B, et al. Apolipoprotein M in patients with chronic kidney disease. Atherosclerosis. 2018;275:304-11. [Crossref] [PubMed]
- Christoffersen C, Benn M, Christensen PM, Gordts PLSM, Roebroek AJM, Frikke-Schmidt R, et al. The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. J Lipid Res. 2012;53(10):2198-204. [Crossref] [PubMed] [PMC]
- Axler O, Ahnström J, Dahlbäck B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res. 2007;48(8):1772-80. [Crossref] [PubMed]
.: İşlem Listesi